Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster hCG for Unruptured Follicle
NCT03580031Phase 4Completed
- Sponsor
- Tanta University
- Start
- Aug 2018
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of human chorionic gonadotropin in luteinized unruptured follicle syndrome (LUFS) (2 arms), sponsored by Tanta University. Primary endpoint: Ovulation rate at 48 hours. Started Aug 2018; status: completed.
02
Drugs
human chorionic gonadotropin
03
Conditions
luteinized unruptured follicle syndrome (LUFS)
Beyond the preview
Go deeper on NCT03580031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580031.